ZIVO Bioscience, Inc. (ZIVO)
USD 16.0
(1.59%)
USD 16.0
(1.59%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 555.71 Thousand USD | -73.82% |
| 2022 | 2.12 Million USD | -76.39% |
| 2021 | 8.99 Million USD | 3983.12% |
| 2020 | 220.17 Thousand USD | -40.39% |
| 2019 | 369.39 Thousand USD | -10.23% |
| 2018 | 411.5 Thousand USD | -90.23% |
| 2017 | 4.21 Million USD | 471.02% |
| 2016 | 737.29 Thousand USD | 914.44% |
| 2015 | 72.68 Thousand USD | -28.65% |
| 2014 | 101.85 Thousand USD | -95.32% |
| 2013 | 2.17 Million USD | 829.22% |
| 2012 | 234 Thousand USD | -49.51% |
| 2011 | 463.49 Thousand USD | 36.35% |
| 2010 | 339.92 Thousand USD | -15.4% |
| 2009 | 401.79 Thousand USD | -7.66% |
| 2008 | 435.14 Thousand USD | 58.32% |
| 2007 | 274.84 Thousand USD | -14.62% |
| 2006 | 321.92 Thousand USD | -51.22% |
| 2005 | 659.93 Thousand USD | 1142.03% |
| 2004 | 53.13 Thousand USD | 439.65% |
| 2003 | 9846.00 USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 816.39 Thousand USD | 46.91% |
| 2024 Q2 | 575.58 Thousand USD | -29.5% |
| 2023 Q2 | 710.33 Thousand USD | -37.03% |
| 2023 Q1 | 1.12 Million USD | -46.87% |
| 2023 FY | 555.71 Thousand USD | -73.82% |
| 2023 Q4 | 555.71 Thousand USD | -73.56% |
| 2023 Q3 | 2.1 Million USD | 195.92% |
| 2022 Q3 | 3.97 Million USD | -32.28% |
| 2022 FY | 2.12 Million USD | -76.39% |
| 2022 Q1 | 7.68 Million USD | -14.48% |
| 2022 Q2 | 5.86 Million USD | -23.72% |
| 2022 Q4 | 2.12 Million USD | -46.54% |
| 2021 Q3 | 10.97 Million USD | -1.19% |
| 2021 Q1 | 648.88 Thousand USD | 194.71% |
| 2021 Q2 | 11.1 Million USD | 1611.19% |
| 2021 FY | 8.99 Million USD | 3983.12% |
| 2021 Q4 | 8.99 Million USD | -18.06% |
| 2020 FY | 220.17 Thousand USD | -40.39% |
| 2020 Q4 | 220.17 Thousand USD | 68.8% |
| 2020 Q1 | 178.91 Thousand USD | -51.56% |
| 2020 Q2 | 222.7 Thousand USD | 24.47% |
| 2020 Q3 | 130.44 Thousand USD | -41.43% |
| 2019 Q3 | 69.9 Thousand USD | -37.72% |
| 2019 Q1 | 103.76 Thousand USD | -74.79% |
| 2019 Q2 | 112.22 Thousand USD | 8.16% |
| 2019 Q4 | 369.39 Thousand USD | 428.45% |
| 2019 FY | 369.39 Thousand USD | -10.23% |
| 2018 Q2 | 739.67 Thousand USD | -73.46% |
| 2018 FY | 411.5 Thousand USD | -90.23% |
| 2018 Q4 | 411.5 Thousand USD | 47.74% |
| 2018 Q1 | 2.78 Million USD | -33.8% |
| 2018 Q3 | 278.53 Thousand USD | -62.34% |
| 2017 Q4 | 4.21 Million USD | 194.58% |
| 2017 FY | 4.21 Million USD | 471.02% |
| 2017 Q2 | 205.54 Thousand USD | -83.41% |
| 2017 Q1 | 1.23 Million USD | 68.01% |
| 2017 Q3 | 1.42 Million USD | 595.33% |
| 2016 Q1 | 349.59 Thousand USD | 381.01% |
| 2016 Q2 | 90.84 Thousand USD | -74.01% |
| 2016 Q3 | 749.91 Thousand USD | 725.47% |
| 2016 Q4 | 737.29 Thousand USD | -1.68% |
| 2016 FY | 737.29 Thousand USD | 914.44% |
| 2015 Q3 | 101.79 Thousand USD | -14.63% |
| 2015 Q4 | 72.68 Thousand USD | -28.6% |
| 2015 Q1 | 183.03 Thousand USD | 79.69% |
| 2015 FY | 72.68 Thousand USD | -28.65% |
| 2015 Q2 | 119.24 Thousand USD | -34.85% |
| 2014 FY | 101.85 Thousand USD | -95.32% |
| 2014 Q4 | 101.85 Thousand USD | -93.61% |
| 2014 Q1 | 1.78 Million USD | -17.97% |
| 2014 Q2 | 1.54 Million USD | -13.6% |
| 2014 Q3 | 1.59 Million USD | 3.37% |
| 2013 FY | 2.17 Million USD | 829.22% |
| 2013 Q3 | 2.01 Million USD | 305.3% |
| 2013 Q2 | 496.2 Thousand USD | 124.29% |
| 2013 Q4 | 2.17 Million USD | 8.12% |
| 2013 Q1 | 221.23 Thousand USD | -5.46% |
| 2012 FY | 234 Thousand USD | -49.51% |
| 2012 Q4 | 234 Thousand USD | 2.24% |
| 2012 Q3 | 228.87 Thousand USD | -35.77% |
| 2012 Q2 | 356.31 Thousand USD | -14.64% |
| 2012 Q1 | 417.42 Thousand USD | -9.94% |
| 2011 Q3 | 366.05 Thousand USD | -6.34% |
| 2011 Q4 | 463.49 Thousand USD | 26.62% |
| 2011 FY | 463.49 Thousand USD | 36.35% |
| 2011 Q2 | 390.84 Thousand USD | 4.18% |
| 2011 Q1 | 375.15 Thousand USD | 10.36% |
| 2010 Q1 | 583.36 Thousand USD | 45.19% |
| 2010 Q3 | 318.88 Thousand USD | -18.87% |
| 2010 Q4 | 339.92 Thousand USD | 6.6% |
| 2010 FY | 339.92 Thousand USD | -15.4% |
| 2010 Q2 | 393.05 Thousand USD | -32.62% |
| 2009 Q4 | 401.79 Thousand USD | -36.33% |
| 2009 Q1 | 366.58 Thousand USD | -15.76% |
| 2009 FY | 401.79 Thousand USD | -7.66% |
| 2009 Q2 | 403.16 Thousand USD | 9.98% |
| 2009 Q3 | 631.04 Thousand USD | 56.52% |
| 2008 Q1 | 332.56 Thousand USD | 21.0% |
| 2008 FY | 435.14 Thousand USD | 58.32% |
| 2008 Q4 | 435.14 Thousand USD | -6.42% |
| 2008 Q3 | 464.97 Thousand USD | 1.08% |
| 2008 Q2 | 460 Thousand USD | 38.32% |
| 2007 Q1 | 877.99 Thousand USD | 172.74% |
| 2007 FY | 274.84 Thousand USD | -14.62% |
| 2007 Q4 | 274.84 Thousand USD | -44.42% |
| 2007 Q3 | 494.5 Thousand USD | 25.5% |
| 2007 Q2 | 394.03 Thousand USD | -55.12% |
| 2006 Q2 | 487.81 Thousand USD | 157.22% |
| 2006 FY | 321.92 Thousand USD | -51.22% |
| 2006 Q4 | 321.92 Thousand USD | -48.79% |
| 2006 Q3 | 628.63 Thousand USD | 28.87% |
| 2006 Q1 | 189.64 Thousand USD | -71.26% |
| 2005 Q2 | 154.6 Thousand USD | 439.25% |
| 2005 Q1 | 28.67 Thousand USD | -46.04% |
| 2005 Q4 | 659.93 Thousand USD | 1362.63% |
| 2005 Q3 | 45.12 Thousand USD | -70.82% |
| 2005 FY | 659.93 Thousand USD | 1142.03% |
| 2004 FY | 53.13 Thousand USD | 439.65% |
| 2004 Q4 | 53.13 Thousand USD | 9.62% |
| 2004 Q3 | 48.47 Thousand USD | -95.46% |
| 2004 Q2 | 1.06 Million USD | 40.74% |
| 2004 Q1 | 758.48 Thousand USD | 7603.48% |
| 2003 Q4 | 9846.00 USD | 0.0% |
| 2003 FY | 9846.00 USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 99.963% |
| Alkermes plc | 2.13 Billion USD | 99.974% |
| Agenus Inc. | 313.91 Million USD | 99.823% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 99.985% |
| Aptorum Group Limited | 20.64 Million USD | 97.308% |
| Ardelyx, Inc. | 297.57 Million USD | 99.813% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 99.927% |
| Bicycle Therapeutics plc | 595.34 Million USD | 99.907% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | 99.246% |
| ChromaDex Corporation | 54.96 Million USD | 98.989% |
| Chimerix, Inc. | 212.77 Million USD | 99.739% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | 98.034% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 99.874% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 99.975% |
| Precision BioSciences, Inc. | 159.78 Million USD | 99.652% |
| Dyadic International, Inc. | 8.21 Million USD | 93.239% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | 98.249% |
| Fortress Biotech, Inc. | 167.52 Million USD | 99.668% |
| Lantern Pharma Inc. | 43.64 Million USD | 98.727% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | 99.656% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | 96.169% |
| Incyte Corporation | 6.78 Billion USD | 99.992% |
| IO Biotech, Inc. | 150.71 Million USD | 99.631% |
| Jaguar Health, Inc. | 50.76 Million USD | 98.905% |
| Novavax, Inc. | 1.85 Billion USD | 99.97% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 99.854% |
| Opthea Limited | 188.79 Million USD | 99.706% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 99.933% |
| ContextLogic Inc. | 423 Million USD | 99.869% |
| MiMedx Group, Inc. | 239.04 Million USD | 99.768% |
| Pyxis Oncology, Inc. | 173.72 Million USD | 99.68% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | 89.251% |
| NextCure, Inc. | 129.41 Million USD | 99.571% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | 98.97% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | 98.487% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | 98.28% |
| Vaxcyte, Inc. | 1.4 Billion USD | 99.961% |
| PDS Biotechnology Corporation | 59.39 Million USD | 99.064% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 99.913% |
| Pharming Group N.V. | 462.85 Million USD | 99.88% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | 98.563% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 99.912% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 97.063% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 97.063% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 99.664% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | 98.773% |
| Acelyrin, Inc. | 742.69 Million USD | 99.925% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | 91.563% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | 91.321% |
| Summit Therapeutics Inc. | 202.94 Million USD | 99.726% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | 99.253% |
| Senti Biosciences, Inc. | 119.48 Million USD | 99.535% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | 99.757% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | 99.67% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | 93.275% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | 88.359% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 99.882% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | 99.551% |
| Wave Life Sciences Ltd. | 274.94 Million USD | 99.798% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 99.882% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | 94.501% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | 99.741% |
| Psyence Biomedical Ltd. | 1.13 Million USD | 50.915% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 99.866% |
| Immix Biopharma, Inc. | 19.92 Million USD | 97.211% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 99.85% |
| MEI Pharma, Inc. | 41.37 Million USD | 98.657% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 98.285% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 99.837% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | 99.526% |
| Fortress Biotech, Inc. | 167.52 Million USD | 99.668% |
| Precigen, Inc. | 151.04 Million USD | 99.632% |
| Clearside Biomedical, Inc. | 34.01 Million USD | 98.366% |
| AlloVir, Inc. | 190.79 Million USD | 99.709% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 99.852% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 99.89% |
| ImmuCell Corporation | 43.8 Million USD | 98.731% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 99.914% |
| Onconetix, Inc. | 88.82 Million USD | 99.374% |
| PureTech Health plc | 693.97 Million USD | 99.92% |
| VYNE Therapeutics Inc. | 97.68 Million USD | 99.431% |
| Elevation Oncology, Inc. | 89.09 Million USD | 99.376% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | 91.04% |
| Seer, Inc. | 436.26 Million USD | 99.873% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | 99.319% |
| Innoviva, Inc. | 1.24 Billion USD | 99.955% |
| Aadi Bioscience, Inc. | 132.42 Million USD | 99.58% |
| ESSA Pharma Inc. | 149.12 Million USD | 99.627% |
| GlycoMimetics, Inc. | 45.31 Million USD | 98.774% |
| GT Biopharma, Inc. | 14.1 Million USD | 96.061% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | 99.82% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | 99.77% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 99.882% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | 98.904% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | 99.416% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | 12.013% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 99.902% |
| Aptose Biosciences Inc. | 12.92 Million USD | 95.7% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | 97.487% |
| Soligenix, Inc. | 9.79 Million USD | 94.328% |
| Century Therapeutics, Inc. | 360.69 Million USD | 99.846% |
| Kura Oncology, Inc. | 448.93 Million USD | 99.876% |
| TScan Therapeutics, Inc. | 272.14 Million USD | 99.796% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | 96.787% |
| Ocean Biomedical, Inc. | 110.91 Million USD | 99.499% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | 99.729% |
| Autolus Therapeutics plc | 375.38 Million USD | 99.852% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | 99.779% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 99.844% |
| Eterna Therapeutics Inc. | 49.13 Million USD | 98.869% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 99.916% |
| GRI Bio, Inc. | 2.95 Million USD | 81.2% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | 94.76% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | 99.674% |
| IGM Biosciences, Inc. | 423.41 Million USD | 99.869% |
| INmune Bio, Inc. | 57 Million USD | 99.025% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 99.75% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 99.338% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 97.872% |
| Entero Therapeutics, Inc. | 6.88 Million USD | 91.926% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | 99.261% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | 99.623% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 99.664% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 99.912% |
| Verastem, Inc. | 149.71 Million USD | 99.629% |
| Abeona Therapeutics Inc. | 64 Million USD | 99.132% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 99.891% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | 99.64% |
| Histogen Inc. | 19.07 Million USD | 97.086% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | 97.547% |
| Surrozen, Inc. | 46.08 Million USD | 98.794% |
| Organovo Holdings, Inc. | 6.34 Million USD | 91.247% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | 87.102% |
| Ovid Therapeutics Inc. | 144.02 Million USD | 99.614% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 95.291% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | 99.262% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | 93.477% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 99.847% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | 96.929% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 99.871% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | 95.594% |
| Apollomics, Inc. | 55.38 Million USD | 98.997% |
| Amarin Corporation plc | 831.68 Million USD | 99.933% |
| Mesoblast Limited | 669.15 Million USD | 99.917% |
| Turnstone Biologics Corp. | 112.81 Million USD | 99.507% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 99.903% |
| Synaptogenix, Inc. | 31.11 Million USD | 98.214% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | 95.439% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 99.899% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | 90.537% |
| Monopar Therapeutics Inc. | 7.34 Million USD | 92.434% |
| Exelixis, Inc. | 2.94 Billion USD | 99.981% |
| Better Therapeutics, Inc. | 22.94 Million USD | 97.578% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 99.848% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 99.93% |
| NLS Pharmaceutics AG | 1.84 Million USD | 69.907% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | 93.035% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 96.218% |
| Gritstone bio, Inc. | 177.76 Million USD | 99.687% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 99.417% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | 96.889% |
| Avid Bioservices, Inc. | 336.55 Million USD | 99.835% |
| Insmed Incorporated | 1.32 Billion USD | 99.958% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | 94.228% |
| MediWound Ltd. | 66.45 Million USD | 99.164% |
| OmniAb, Inc. | 401.98 Million USD | 99.862% |
| Alector, Inc. | 621.82 Million USD | 99.911% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 99.845% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | 89.667% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 99.02% |
| Zai Lab Limited | 1.03 Billion USD | 99.946% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 99.884% |
| Aura Biosciences, Inc. | 255.07 Million USD | 99.782% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 99.926% |
| Immunic, Inc. | 54.29 Million USD | 98.977% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | 99.791% |
| Veracyte, Inc. | 1.13 Billion USD | 99.951% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | 95.3% |
| FibroGen, Inc. | 423.52 Million USD | 99.869% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | 84.181% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | 88.268% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | 89.765% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 99.995% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | 93.689% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 99.893% |
| TG Therapeutics, Inc. | 329.58 Million USD | 99.831% |
| Galecto, Inc. | 38.22 Million USD | 98.546% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 98.062% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 99.987% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | 99.764% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | 97.763% |
| XBiotech Inc. | 227.24 Million USD | 99.755% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 99.417% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | 99.61% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | 99.806% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | 99.565% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 99.855% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 99.963% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 99.848% |
| Vaxxinity, Inc. | 44.35 Million USD | 98.747% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 99.893% |
| Gain Therapeutics, Inc. | 18.6 Million USD | 97.014% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | 99.818% |
| NexImmune, Inc. | 8.59 Million USD | 93.534% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | 94.814% |
| Marker Therapeutics, Inc. | 17.12 Million USD | 96.755% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.998% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | 97.491% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -41.668% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | 99.679% |
| Ainos, Inc. | 31.84 Million USD | 98.255% |
| Pluri Inc. | 39.52 Million USD | 98.594% |
| Prothena Corporation plc | 696.38 Million USD | 99.92% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | 99.803% |
| Celularity Inc. | 143.88 Million USD | 99.614% |
| Rallybio Corporation | 115.62 Million USD | 99.519% |
| Cue Biopharma, Inc. | 61.53 Million USD | 99.097% |
| MeiraGTx Holdings plc | 458.16 Million USD | 99.879% |
| Omeros Corporation | 378.26 Million USD | 99.853% |
| Humacyte, Inc. | 128.22 Million USD | 99.567% |
| Immunocore Holdings plc | 597 Million USD | 99.907% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | 98.222% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | 99.189% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 99.947% |
| CalciMedica, Inc. | 12.18 Million USD | 95.439% |
| Cabaletta Bio, Inc. | 253.65 Million USD | 99.781% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | 99.675% |
| Scholar Rock Holding Corporation | 311.03 Million USD | 99.821% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 99.902% |
| Pulmatrix, Inc. | 33.95 Million USD | 98.364% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | 97.953% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | 99.605% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 99.957% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | 99.573% |
| Cytokinetics, Incorporated | 824.31 Million USD | 99.933% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 97.369% |
| Nutriband Inc. | 7.51 Million USD | 92.607% |
| Protara Therapeutics, Inc. | 78.95 Million USD | 99.296% |
| Vor Biopharma Inc. | 209.82 Million USD | 99.735% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 99.992% |
| Evogene Ltd. | 51.1 Million USD | 98.913% |
| ProKidney Corp. | 420.55 Million USD | 99.868% |
| Applied Therapeutics, Inc. | 54.83 Million USD | 98.987% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | 94.163% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 99.898% |
| CorMedix Inc. | 82.05 Million USD | 99.323% |
| BioLineRx Ltd. | 63.92 Million USD | 99.131% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 99.862% |
| Galectin Therapeutics Inc. | 28.2 Million USD | 98.029% |
| Atai Life Sciences N.V. | 293.47 Million USD | 99.811% |
| Renovaro Biosciences Inc. | 163.12 Million USD | 99.659% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | 99.564% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 99.901% |
| Sagimet Biosciences Inc. | 96.71 Million USD | 99.425% |
| MediciNova, Inc. | 66.26 Million USD | 99.161% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | 99.368% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | 87.547% |
| GeoVax Labs, Inc. | 9.28 Million USD | 94.014% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 99.906% |
| Biomea Fusion, Inc. | 199.92 Million USD | 99.722% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 99.971% |
| Mereo BioPharma Group plc | 66.49 Million USD | 99.164% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 99.885% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 99.909% |
| Absci Corporation | 234.48 Million USD | 99.763% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | 92.403% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 99.837% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | 99.663% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 99.894% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | 99.8% |
| Allakos Inc. | 243.61 Million USD | 99.772% |
| Imunon, Inc. | 21.91 Million USD | 97.465% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | 99.784% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 99.911% |
| BioAtla, Inc. | 119.65 Million USD | 99.536% |
| NLS Pharmaceutics AG | 1.84 Million USD | 69.907% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | 82.742% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 99.914% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | 99.421% |
| XOMA Corporation | 234.3 Million USD | 99.763% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | 99.749% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 99.558% |
| aTyr Pharma, Inc. | 122.06 Million USD | 99.545% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | 99.639% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 99.904% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 99.887% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | 99.497% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | 96.334% |
| Akari Therapeutics, Plc | 4.35 Million USD | 87.24% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 96.738% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 99.968% |
| Lexaria Bioscience Corp. | 3.08 Million USD | 81.981% |
| UroGen Pharma Ltd. | 178.31 Million USD | 99.688% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 99.882% |
| Orgenesis Inc. | 14.55 Million USD | 96.181% |
| Entera Bio Ltd. | 11.76 Million USD | 95.277% |
| GH Research PLC | 226.3 Million USD | 99.754% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | 98.984% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | 99.483% |
| Xencor, Inc. | 952.69 Million USD | 99.942% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | 92.861% |
| Replimune Group, Inc. | 487.72 Million USD | 99.886% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | 93.115% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 99.914% |
| Lexaria Bioscience Corp. | 3.08 Million USD | 81.981% |
| Portage Biotech Inc. | 7.77 Million USD | 92.856% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | 87.547% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | 99.799% |
| OncoCyte Corporation | 74.89 Million USD | 99.258% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | 72.669% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | 90.397% |
| Purple Biotech Ltd. | 44.3 Million USD | 98.746% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | 98.372% |
| scPharmaceuticals Inc. | 94.47 Million USD | 99.412% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | 96.92% |
| HilleVax, Inc. | 344.43 Million USD | 99.839% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | 82.503% |
| Tharimmune, Inc. | 10.94 Million USD | 94.923% |
| Genprex, Inc. | 10.67 Million USD | 94.792% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 99.888% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | 99.423% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | 77.093% |
| Virios Therapeutics, Inc. | 4.16 Million USD | 86.659% |
| OKYO Pharma Limited | 1.54 Million USD | 63.944% |
| Savara Inc. | 177.56 Million USD | 99.687% |
| Curis, Inc. | 77.28 Million USD | 99.281% |
| Daré Bioscience, Inc. | 21.28 Million USD | 97.389% |
| Carmell Therapeutics Corporation | 63.94 Million USD | 99.131% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | 93.127% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | 97.131% |
| BeiGene, Ltd. | 5.8 Billion USD | 99.99% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 95.433% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 99.973% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 99.845% |
| Erasca, Inc. | 395.29 Million USD | 99.859% |
| bluebird bio, Inc. | 619.16 Million USD | 99.91% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | 87.146% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.992% |
| DBV Technologies S.A. | 182.98 Million USD | 99.696% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | 87.146% |
| Moderna, Inc. | 18.42 Billion USD | 99.997% |
| Vincerx Pharma, Inc. | 18.21 Million USD | 96.949% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | 95.204% |
| Molecular Templates, Inc. | 35.38 Million USD | 98.429% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | 99.598% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 99.93% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | 99.817% |
| Spruce Biosciences, Inc. | 103.94 Million USD | 99.465% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 99.881% |
| Cogent Biosciences, Inc. | 313.43 Million USD | 99.823% |
| MacroGenics, Inc. | 306.82 Million USD | 99.819% |
| RenovoRx, Inc. | 1.46 Million USD | 62.093% |
| Adicet Bio, Inc. | 207.29 Million USD | 99.732% |
| Prime Medicine, Inc. | 193.85 Million USD | 99.713% |
| Aditxt, Inc. | 44.57 Million USD | 98.753% |
| Adagene Inc. | 115.72 Million USD | 99.52% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | 87.524% |
| Quantum-Si incorporated | 298.25 Million USD | 99.814% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 99.963% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | 92.791% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 99.842% |
| SciSparc Ltd. | 11.18 Million USD | 95.03% |
| Vericel Corporation | 353.65 Million USD | 99.843% |
| Revelation Biosciences, Inc. | 12.21 Million USD | 95.45% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | 99.023% |
| Generation Bio Co. | 374.75 Million USD | 99.852% |
| Astria Therapeutics, Inc. | 254.66 Million USD | 99.782% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | 99.65% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 99.837% |
| Invivyd, Inc. | 229.18 Million USD | 99.758% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 99.934% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | 95.433% |
| Spero Therapeutics, Inc. | 182.39 Million USD | 99.695% |
| Artelo Biosciences, Inc. | 20.42 Million USD | 97.279% |
| 2seventy bio, Inc. | 565.42 Million USD | 99.902% |
| ADMA Biologics, Inc. | 329.18 Million USD | 99.831% |
| Clene Inc. | 52.34 Million USD | 98.938% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | 99.054% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | 99.572% |
| GeoVax Labs, Inc. | 9.28 Million USD | 94.014% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 99.915% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | 99.464% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | 99.574% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | 99.43% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 99.217% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | 99.771% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 99.972% |
| Evaxion Biotech A/S | 12.88 Million USD | 95.688% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | 99.78% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 99.926% |
| Trevena, Inc. | 40.6 Million USD | 98.631% |
| Surrozen, Inc. | 46.08 Million USD | 98.794% |
| Tyra Biosciences, Inc. | 225.85 Million USD | 99.754% |
| Cingulate Inc. | 3.49 Million USD | 84.083% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | 96.658% |
| Unity Biotechnology, Inc. | 65.69 Million USD | 99.154% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | 95.244% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | 99.793% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 99.926% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | 99.559% |
| Clearmind Medicine Inc. | 4.32 Million USD | 87.149% |
| Kronos Bio, Inc. | 213.27 Million USD | 99.739% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | 99.652% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | 93.508% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 99.849% |
| Statera Biopharma, Inc. | 21.16 Million USD | 97.375% |
| ImmunityBio, Inc. | 504.45 Million USD | 99.89% |
| Korro Bio, Inc. | 221.66 Million USD | 99.749% |
| Kineta, Inc. | 10.28 Million USD | 94.595% |
| BioVie Inc. | 25.2 Million USD | 97.796% |
| Codexis, Inc. | 136.56 Million USD | 99.593% |
| Celularity Inc. | 143.88 Million USD | 99.614% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 99.913% |
| Celcuity Inc. | 191.21 Million USD | 99.709% |
| Virax Biolabs Group Limited | 5.48 Million USD | 89.867% |
| Cibus, Inc. | 544.41 Million USD | 99.898% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | 99.559% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 97.295% |
| IN8bio, Inc. | 33.7 Million USD | 98.351% |
| Kodiak Sciences Inc. | 479.37 Million USD | 99.884% |
| Annexon, Inc. | 297.67 Million USD | 99.813% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | 99.679% |
| Assembly Biosciences, Inc. | 137.46 Million USD | 99.596% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | 97.353% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 99.981% |
| Eyenovia, Inc. | 28.77 Million USD | 98.069% |
| Puma Biotechnology, Inc. | 230.52 Million USD | 99.759% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | 92.307% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | 99.088% |
| Arcellx, Inc. | 825.13 Million USD | 99.933% |
| Cardiff Oncology, Inc. | 81.63 Million USD | 99.319% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 99.88% |
| Regulus Therapeutics Inc. | 30.75 Million USD | 98.193% |
| Moolec Science SA | 24.05 Million USD | 97.689% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | 99.821% |
| Geron Corporation | 394.07 Million USD | 99.859% |
| LAVA Therapeutics N.V. | 101.71 Million USD | 99.454% |
| Royalty Pharma plc | 16.38 Billion USD | 99.997% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 99.907% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | 92.055% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | 95.38% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | 99.754% |
| Humacyte, Inc. | 128.22 Million USD | 99.567% |
| Structure Therapeutics Inc. | 482.01 Million USD | 99.885% |
| 89bio, Inc. | 596.26 Million USD | 99.907% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | 99.78% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | 69.961% |
| Genelux Corporation | 27.89 Million USD | 98.008% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | 99.378% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | 99.758% |
| Notable Labs, Ltd. | 19.54 Million USD | 97.156% |
| Liquidia Corporation | 120.43 Million USD | 99.539% |
| Mustang Bio, Inc. | 17.74 Million USD | 96.868% |
| Immunovant, Inc. | 666.71 Million USD | 99.917% |
| Quantum-Si incorporated | 298.25 Million USD | 99.814% |
| Arbutus Biopharma Corporation | 144.4 Million USD | 99.615% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | 98.974% |
| Vera Therapeutics, Inc. | 175.54 Million USD | 99.683% |
| Acasti Pharma Inc. | 73.3 Million USD | 99.242% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | 87.793% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 97.872% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 99.942% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | 89.292% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | 97.561% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | 98.923% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | 99.692% |
| PepGen Inc. | 143.05 Million USD | 99.612% |
| Moleculin Biotech, Inc. | 38.21 Million USD | 98.546% |
| United Therapeutics Corporation | 7.16 Billion USD | 99.992% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | 97.103% |
| Solid Biosciences Inc. | 164.93 Million USD | 99.663% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | 90.537% |
| Immuneering Corporation | 102.58 Million USD | 99.458% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | 87.102% |
| Silo Pharma, Inc. | 7.74 Million USD | 92.826% |
| Belite Bio, Inc | 94.64 Million USD | 99.413% |
| XOMA Corporation | 234.3 Million USD | 99.763% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | 99.762% |
| Bionomics Limited | 27.64 Million USD | 97.99% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 99.862% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 99.483% |
| uniQure N.V. | 831.68 Million USD | 99.933% |
| Cassava Sciences, Inc. | 151.66 Million USD | 99.634% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | 87.524% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | 99.797% |
| Forte Biosciences, Inc. | 38.98 Million USD | 98.574% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | 86.357% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | 98.491% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | 92.307% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | 84.181% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | 95.299% |
| Altimmune, Inc. | 210.64 Million USD | 99.736% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 99.929% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 99.483% |
| Compugen Ltd. | 121.33 Million USD | 99.542% |
| Peak Bio, Inc. | 2.59 Million USD | 78.597% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | 99.678% |
| Benitec Biopharma Inc. | 52.21 Million USD | 98.936% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 99.837% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | 98.402% |
| Zura Bio Limited | 100.84 Million USD | 99.449% |
| PolyPid Ltd. | 15.37 Million USD | 96.385% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | 99.534% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | 98.402% |
| Instil Bio, Inc. | 325.63 Million USD | 99.829% |
| argenx SE | 4.54 Billion USD | 99.988% |
| Immunome, Inc. | 148.54 Million USD | 99.626% |
| Compass Therapeutics, Inc. | 156.87 Million USD | 99.646% |
| Verona Pharma plc | 308.12 Million USD | 99.82% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | 99.361% |
| Shattuck Labs, Inc. | 159.56 Million USD | 99.652% |
| CervoMed Inc. | 9.97 Million USD | 94.428% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | 99.705% |
| Plus Therapeutics, Inc. | 11.38 Million USD | 95.12% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | 99.69% |
| Moolec Science SA | 24.05 Million USD | 97.689% |
| Enveric Biosciences, Inc. | 6.11 Million USD | 90.916% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | 99.679% |
| AnaptysBio, Inc. | 452.38 Million USD | 99.877% |
| Design Therapeutics, Inc. | 289.64 Million USD | 99.808% |
| Leap Therapeutics, Inc. | 72.82 Million USD | 99.237% |
| NeurAxis, Inc. | 509.49 Thousand USD | -9.071% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | 89.743% |
| Lumos Pharma, Inc. | 40.63 Million USD | 98.633% |
| Achilles Therapeutics plc | 161.45 Million USD | 99.656% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | 99.361% |
| 180 Life Sciences Corp. | 5.25 Million USD | 89.434% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | 99.211% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | 93.508% |
| Nutriband Inc. | 7.51 Million USD | 92.607% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | 99.782% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | 99.721% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | 99.271% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | 99.04% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 99.894% |
| Palisade Bio, Inc. | 14.05 Million USD | 96.045% |
| Tourmaline Bio, Inc. | 210.29 Million USD | 99.736% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 99.962% |
| Neurogene Inc. | 222.57 Million USD | 99.75% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 99.914% |
| AEON Biopharma, Inc. | 6.84 Million USD | 91.881% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 99.877% |
| Sesen Bio, Inc. | 189.17 Million USD | 99.706% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | 99.796% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | 95.947% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 99.929% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | 99.792% |
| Athira Pharma, Inc. | 160.24 Million USD | 99.653% |
| Vaccinex, Inc. | 3.63 Million USD | 84.695% |
| HCW Biologics Inc. | 28.51 Million USD | 98.051% |
| XOMA Corporation | 234.3 Million USD | 99.763% |
| Nektar Therapeutics | 398.03 Million USD | 99.86% |
| Arvinas, Inc. | 1.3 Billion USD | 99.957% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 96.738% |
| Merus N.V. | 458.49 Million USD | 99.879% |
| Omega Therapeutics, Inc. | 204.36 Million USD | 99.728% |
| Quince Therapeutics, Inc. | 180.2 Million USD | 99.692% |
| Rezolute, Inc. | 132.73 Million USD | 99.581% |
| Clene Inc. | 52.34 Million USD | 98.938% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | 96.276% |
| BeyondSpring Inc. | 24.8 Million USD | 97.76% |
| Synlogic, Inc. | 75.55 Million USD | 99.264% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | 95.315% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | 94.065% |
| Peak Bio, Inc. | 2.59 Million USD | 78.597% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | 99.682% |
| Krystal Biotech, Inc. | 818.35 Million USD | 99.932% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | 99.769% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 99.923% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | 84.465% |
| MannKind Corporation | 475.19 Million USD | 99.883% |
| Ikena Oncology, Inc. | 192.09 Million USD | 99.711% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | 95.845% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | 99.523% |
| Gossamer Bio, Inc. | 311.91 Million USD | 99.822% |
| CohBar, Inc. | 16.36 Million USD | 96.604% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | 98.42% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | 92.403% |
| Legend Biotech Corporation | 1.84 Billion USD | 99.97% |
| Mural Oncology plc | 301.74 Million USD | 99.816% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 98.22% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | 90.217% |
| Disc Medicine, Inc. | 367.99 Million USD | 99.849% |
| Champions Oncology, Inc. | 26.13 Million USD | 97.873% |
| REGENXBIO Inc. | 573.97 Million USD | 99.903% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | 79.479% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 99.64% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | 95.398% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 99.837% |
| Vaxart, Inc. | 91.83 Million USD | 99.395% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | 99.072% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | 99.625% |
| Cellectis S.A. | 334.27 Million USD | 99.834% |
| Longeveron Inc. | 12.17 Million USD | 95.437% |
| Repare Therapeutics Inc. | 253.9 Million USD | 99.781% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 99.983% |
| Inozyme Pharma, Inc. | 200.84 Million USD | 99.723% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 99.973% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | 65.802% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | 99.8% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | 99.659% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | 99.599% |
| Anixa Biosciences, Inc. | 25.52 Million USD | 97.823% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.998% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 99.952% |
| Revelation Biosciences, Inc. | 12.21 Million USD | 95.45% |
| Veru Inc. | 50.59 Million USD | 98.902% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | 98.78% |
| Cingulate Inc. | 3.49 Million USD | 84.083% |
| Passage Bio, Inc. | 150.54 Million USD | 99.631% |
| Context Therapeutics Inc. | 16.06 Million USD | 96.54% |
| Exicure, Inc. | 11.58 Million USD | 95.201% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 99.852% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | 99.656% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | 96.819% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 99.833% |
| Nuvalent, Inc. | 732.38 Million USD | 99.924% |
| ABVC BioPharma, Inc. | 14.94 Million USD | 96.281% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | 99.379% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | 96.084% |
| OmniAb, Inc. | 401.98 Million USD | 99.862% |
| Anew Medical, Inc. | 19.45 Million USD | 97.144% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | 97.921% |
| Lipocine Inc. | 23 Million USD | 97.584% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | 99.603% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | 99.818% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 99.338% |
| G1 Therapeutics, Inc. | 121.54 Million USD | 99.543% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | 92.997% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 99.937% |
| Ocugen, Inc. | 64.54 Million USD | 99.139% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | 99.554% |
| Q32 Bio Inc. | 306.11 Million USD | 99.818% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | 86.794% |
| Alumis Inc. Common Stock | 89.61 Million USD | 99.38% |
| Equillium, Inc. | 50.53 Million USD | 98.9% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | 99.261% |
| Coya Therapeutics, Inc. | 41.27 Million USD | 98.654% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | 67.327% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 97.874% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 99.138% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | 85.09% |
| Dominari Holdings Inc. | 57.55 Million USD | 99.035% |
| Edesa Biotech, Inc. | 8.89 Million USD | 93.749% |
| vTv Therapeutics Inc. | 11.01 Million USD | 94.956% |
| Bio-Techne Corporation | 2.81 Billion USD | 99.98% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 99.941% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 99.932% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | 99.8% |
| Candel Therapeutics, Inc. | 41.7 Million USD | 98.667% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 99.917% |
| Nkarta, Inc. | 378.88 Million USD | 99.853% |
| BioCardia, Inc. | 2.98 Million USD | 81.396% |
| Iterum Therapeutics plc | 26.25 Million USD | 97.884% |